Horace Mann Set to Reveal Fourth-Quarter 2024 Financial Performance
January 14, 2025 - 01:22
SPRINGFIELD, Ill., January 13, 2025—Horace Mann Educators Corporation has announced that it will disclose its financial results for the fourth quarter of 2024 on Wednesday, February 5. The announcement will be made after the market closes, providing investors and stakeholders with a comprehensive overview of the company's performance during the quarter.
In conjunction with the earnings release, the company will also provide an investor supplement and an investor presentation. These materials are expected to offer deeper insights into the financial results, strategic initiatives, and future outlook of Horace Mann. This event is highly anticipated by analysts and investors alike, as it will shed light on the company’s operational effectiveness and market positioning.
As the date approaches, stakeholders are encouraged to prepare for the release of this important financial information, which will be accessible through the company's investor relations platform.
MORE NEWS
May 14, 2026 - 00:55
Aeluma Announces Third Quarter Fiscal 2026 Financial ResultsAeluma, Inc., a company specializing in compound semiconductor technologies, has released its financial results for the third quarter of fiscal year 2026. The report comes alongside several major...
May 13, 2026 - 11:31
MCK Q1 Deep Dive: Revenue Misses Analyst Expectations as Margin Initiatives ContinueHealthcare distributor McKesson reported first-quarter earnings that missed revenue expectations, though the company continued to push ahead with margin-focused initiatives. For the quarter ending...
May 12, 2026 - 23:07
Prudential Financial Declares Quarterly Dividend on Common StockNEWARK, N.J., May 12, 2026 -- Prudential Financial, Inc. has declared a quarterly dividend of $1.40 per share on its common stock. The payment is scheduled for June 11, 2026, and will go to...
May 12, 2026 - 03:06
Cellectis Reports First Quarter 2026 Financial ResultsCellectis has announced its financial results for the first quarter of 2026, alongside updates on its clinical pipeline and preclinical research programs. The company is advancing its pivotal...